DailyIQ
|
Sector:HealthcareAll sectors
Last updated just now

COR·Cencora, Inc.

$.
-. (-.%)
After Hours
High
$276.24
Open
$273.09
Market Cap
53.49B
52W High
$377.54
Low
$270.23
P. Close
$270.84
P/E
20.99
52W Low
$244.82
Fwd P/E
13.77
Mean Target
-
Technical Score (1D)
18
SELL
News Sentiment
45
MIXED
Cencora (COR) recently updated its fiscal year 2026 adjusted diluted earnings per share guidance upwards to a range of $17.70 to $17.90, driven by opportunistic share repurchases in May. This outlook revision is further supported by the announcement of a new $2.0 billion share repurchase program, signaling management's confidence in the company's financial trajectory and commitment to shareholder returns. These buybacks align with prior shareholder return expectations and contribute to the company's consistent growth, which an investment firm highlighted as outperforming valuation changes. However, investor confidence is being tested by ongoing legal probes from multiple law firms investigating Cencora for potential securities law violations. These investigations were triggered by the company's Q2 results, which fell below revenue estimates, and a subsequent reduction in its full-year revenue growth forecast. The probes will examine whether Cencora misled investors regarding its financial performance and outlook. This legal scrutiny adds a layer of risk for investors already digesting recent financial headwinds, including Q1 revenue that missed expectations due to accelerated brand-to-biosimilar conversions and manufacturer price reductions. Despite these challenges, Cencora's management remains confident in the resilience of its business model, supported by growth in specialty pharmaceuticals and recent acquisitions. Analysts generally maintain a positive outlook, reinforcing a bullish view on the company's future earnings and expansion capabilities, with Cencora having consistently outperformed the general market over the past year. Looking ahead, investors should monitor any further insights from upcoming investor events and the outcomes of the ongoing legal investigations.
Earnings Summary
Cencora, Inc., formerly AmerisourceBergen Corporation, is a global pharmaceutical distribution and services company operating within the Healthcare sector's Medical Distribution industry. The company plays a crucial role in the healthcare supply chain, sourcing and distributing a wide range of pharmaceutical products and offering value-added services to healthcare providers and manufacturers. In its most recent reported quarters, Cencora demonstrated a mixed performance. For Q2 2026, the company reported actual EPS of $4.75, significantly beating the estimated $4.335, although revenue of $78.36 billion missed the estimate of $87.23 billion. This followed Q3 2026 where actual EPS was $3.84 against an estimate of $3.785, and revenue was not provided. Prior to this, in Q1 2025, EPS was $4.42, beating the estimate of $4.095, with revenue of $75.45 billion not estimated. The company's EPS has shown an upward trend, beating estimates in Q4 2024 ($3.73 vs $3.52), Q1 2025 ($4.42 vs $4.095), and Q2 2026 ($4.75 vs $4.335), while missing in Q3 2025 ($3.84 vs $3.785). Revenue performance has been inconsistent, with Q2 2026 revenue missing estimates. Recent news indicates Cencora has raised its fiscal year 2026 adjusted diluted EPS guidance to $17.70-$17.90, supported by opportunistic share repurchases and a new $2.0 billion buyback program. However, investor confidence is being tested by ongoing securities law violation investigations triggered by Q2 results that missed revenue estimates and a reduced full-year revenue forecast. Investors should watch for further developments in the legal probes and monitor the company's ability to sustain its EPS growth trajectory amidst these challenges and any further guidance updates.

EPS

EstBeatMiss
$3.34$3.74$4.14$4.53$4.93Q4'24Q1'25Q2'25Q3'25Q2'26Q3'26
QtrEstActual+/−
Q3'26$4.37 - -
Q2'26$4.33$4.75+9.6%
Q3'25$3.79$3.84+1.4%
Q2'25$3.84$4.00+4.2%
Q1'25$4.10$4.42+7.9%
Q4'24$3.52$3.73+6.0%

Revenue

EstBeatMiss
$73.7B$77.5B$81.3B$85.2B$89.0BQ4'24Q1'25Q2'25Q3'25Q2'26Q3'26
QtrEstActual+/−
Q3'26$85.3B - -
Q2'26$87.2B$78.4B-10.2%
Q3'25 - $83.7B -
Q2'25 - $80.7B -
Q1'25 - $75.5B -
Q4'24 - $81.5B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

COR Stock Snapshot

COR is currently trading at $270.46, giving Cencora, Inc. a market cap of 53.49B and a P/E ratio of 21.0. Today's range spans $270.23–$276.24, with shares opening at $273.09 and moving down $0.38 (0.1%) from the prior close. DailyIQ's technical score sits at 18/100 (SELL) with a news sentiment reading of 45/100.

Over the past year COR has traded between $244.82 and $377.54 - the current price is +10.5% off the 52-week low and -28.4% from the high.

The bearish momentum on Cencora, Inc. (COR) - 18/100 (SELL), sentiment neutral at 45/100, price $270.46 (in the lower half of its 52-week range) - is the type of setup where stop-loss selling from long-side momentum strategies amplifies the initial technical weakness. The current P/E ratio stands at 21.0. At 53.49B in Healthcare market cap, the 52-week range of $244.82–$377.54 provides the structural reference, and the lower end of that range becomes the next key test if the current SELL signal persists.

Analyst coverage for COR becomes a double-edged factor in a SELL phase: at 53.49B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 18/100 technical reading and neutral sentiment (45/100) at $270.46 (in the lower half of its 52-week range) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $244.82–$377.54 range establishes where that repricing lands.